Everything below concerns reconstitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Stephen Dank (born c. 1963) is an Australian biochemist who worked as a sports scientist at several professional sports club. He is known for his key role in two major sports drug cheating scandals, the Essendon Football Club supplements saga and the Cronulla-Sutherland Sharks supplements saga, where he injected players with illegal substances to improve their performance. He is known for his unorthodox treatment and diagnostic methods, including using calf blood and profiling players' DNA. Des Hasler described Dank as 'a great analytical thinker', in particular highlighting his contributions in the area of GPS application, statistical science, and altitude simulation training. In light of his unorthodox treatment methods, in November 2016 Dank was given a life-long ban from association with the Australian Football League. On 28 November 2016, the Australian Sports Anti-Doping Authority (ASADA), (known as Sport Integrity Australia since July 1 2020), officially acknowledged the decision of the AFL Appeal Board He worked with National Rugby League clubs the Manly Sea Eagles and Cronulla Sharks and Australian rules football clubs, Essendon Football Club and the Gold Coast Suns.
== Diagnosis == Buried bumper syndrome may be suspected based on features consistent with this disorder. The diagnosis is confirmed either endoscopically (via upper endoscopy) or with computed tomography. Upper endoscopy may reveal overgrowth of stomach tissue over the internal bumper (incomplete buried bumper syndrome). If the bumper has eroded deep into the gastric mucosa, it may not be visualized during endoscopic evaluation (complete buried bumper syndrome).
At WrestleMania 13, Hart defeated Austin in a highly acclaimed submission match with Ken Shamrock as a special referee. During the match, Hart and Austin made a double turn, changing Austin to babyface. Austin portrayed an anti-hero instead of a traditional babyface. Austin's public popularity surged following the Wrestlemania clash, and Austin 3:16 merchandise t-shirts were reported in May 1997 to have become the best-selling WWF t-shirts since Hulkamania. Austin eventually got his revenge on Hart in the main event of In Your House 14: Revenge of the 'Taker, defeating him in a match to determine the next contender to The Undertaker's WWF Championship. Austin won when Hart was disqualified due to assistance from The British Bulldog. At In Your House 15: A Cold Day in Hell, Austin had The Undertaker down with the Stone Cold Stunner but was distracted by Pillman, allowing The Undertaker to recover and perform a Tombstone Piledriver for the victory. Austin won the WWF Tag Team Championship twice: first with Shawn Michaels, who vacated the title due to an injury, and with Dude Love. Austin also feuded with Owen Hart, facing him during a ten-man Tag Team match at In Your House 16: Canadian Stampede. At SummerSlam 1997, Austin defeated Owen for the Intercontinental Championship. During the match, Owen botched a Sit-out Piledriver and dropped Austin on his head, resulting in a legitimate bruised spinal cord and temporary paralysis for Austin. Due to the severity of his neck injury, Austin was forced to relinquish both championships.
Customs and Border Protection, United States Border Patrol, and the United States Coast Guard), state (e.g., Massachusetts State Police Special Investigation Unit, New Jersey State Police organized crime unit, Pennsylvania State Police organized crime unit and the New York State Police Bureau of Criminal Investigation) and city (e.g., New York City Police Department Organized Crime Unit, Philadelphia Police Department Organized crime unit, Chicago Police Organized Crime Unit and the Los Angeles Police Department Special Operations Division) law enforcement agencies.
=== Basic research and translational preclinical animal model research === Jennette, in collaboration with Falk, and UNC faculty associates Hong Xiao and Peiqi Hu, and other faculty and trainees, made multiple discoveries about the cellular and molecular mechanisms that cause ANCA disease. He, Falk, and their research associates published the first demonstration that ANCA can activate neutrophils in vitro, and the first in vivo animal model confirming that ANCA antibodies cause glomerulonephritis by inducing glomerulonephritis and vasculitis in mice by intravenous injection of anti-MPO antibodies. This model has been used to make discoveries about the pathogenesis of ANCA disease, including the discovery of a key role for alternative complement pathway activation and C5a receptor engagement, which can be targeted by a novel small molecular inhibitor of C5a receptor (Avacopan). This approach to therapy was FDA-approved for patient care in 2021.
Sources: en.wikipedia.org
The protein design conformational space can be represented as a tree, where the protein residues are ordered in an arbitrary way, and the tree branches at each of the rotamers in a residue. Branch and bound algorithms use this representation to efficiently explore the conformation tree: At each branching, branch and bound algorithms bound the conformation space and explore only the promising branches. A popular search algorithm for protein design is the A* search algorithm. A* computes a lower-bound score on each partial tree path that lower bounds (with guarantees) the energy of each of the expanded rotamers. Each partial conformation is added to a priority queue and at each iteration the partial path with the lowest lower bound is popped from the queue and expanded. The algorithm stops once a full conformation has been enumerated and guarantees that the conformation is the optimal. The A* score f in protein design consists of two parts, f=g+h. g is the exact energy of the rotamers that have already been assigned in the partial conformation. h is a lower bound on the energy of the rotamers that have not yet been assigned. Each is designed as follows, where d is the index of the last assigned residue in the partial conformation.
=== Cancer-associated expression === ITGA1 expression is frequently altered during tumor development and progression. In pancreatic ductal adenocarcinoma (PDAC), ITGA1 expression is typically low or absent in normal pancreatic ductal epithelial and acinar cells. Expression becomes increased during malignant transformation, however. Elevated ITGA1 expression is detected in pancreatic intraepithelial neoplasia (PanIN) lesions and PDAC tumors, with expression primarily found in tumor epithelial cells. Approximately 42% of PDAC patient samples demonstrate high ITGA1 protein expression. PDAC cell models also show increased surface ITGA1 expression, including enrichment within ALDH1hi stem-like tumor cell populations, suggesting association with highly tumorigenic cell states. In retinoblastoma (Rb), ITGA1 is significantly upregulated compared to normal retinal tissue. Transcriptomic analysis identified ITGA1 as one of the most highly upregulated integrin subunits in Rb samples. Increased ITGA1 expression was confirmed at the protein level by immunohistochemistry, and retinoblastoma Y79 cells showed elevated ITGA1 and ITGB1 expression when compared with normal retinal pigment epithelial ARPE-19 cells. These findings indicate. tumor-associated activation of α1β1 integrin signaling in retinoblastoma. In glioma, ITGA1 expression is associated with chemotherapy resistance. TMZ-resistant glioma tissues and U87/R glioma cells exhibit increased ITGA1 mRNA and protein expression compared with TMZ-sensitive controls.
=== Bulimia nervosa === A 2011 systematic review discussed seven trials that compared fluoxetine to a placebo in the treatment of bulimia nervosa, six of which found a statistically significant reduction in symptoms such as vomiting and binge eating. However, no difference was observed between treatment arms when fluoxetine and psychotherapy were compared to psychotherapy alone.
== Adverse effects == The US prescription label includes a boxed warning for allergic reactions including anaphylaxis. The most common side effects include upper respiratory tract infection, ear infection, fever, anemia, cough, vomiting, diarrhea, rash, COVID-19, runny nose, nasal congestion, fall, headache, skin abrasion, and hives.
Sources: en.wikipedia.org
Plant resin is a viscoelastic solid polymer. When left in a container, it will flow slowly as a liquid to conform to the contours of its container. If struck with greater force, however, it will shatter as a solid.
== Types == The following is a comparison of different types of prostaglandin, including prostaglandin I2 (prostacyclin; PGI2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), and prostaglandin F2α (PGF2α).
In 2009, Cullis co-founded a company called Acuitas Therapeutics to commercialize his LNP research; Acuitas worked on developing LNPs for Alnylam Pharmaceuticals's siRNA drugs. In 2018, the FDA approved Alnylam's siRNA drug Onpattro (patisiran), the first drug to use LNPs as the drug delivery system. By that point in time, siRNA drug developers like Alnylam were already looking at other options for future drugs like chemical conjugate systems, but during the 2010s, the earlier research into using LNPs for siRNA became a foundation for new research into using LNPs for mRNA. Lipids intended for short siRNA strands did not work well for much longer mRNA strands, which led to extensive research during the mid-2010s into the creation of novel ionizable cationic lipids appropriate for mRNA. As of late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines. Moderna uses its own proprietary ionizable cationic lipid called SM-102, while Pfizer and BioNTech licensed an ionizable cationic lipid called ALC-0315 from Acuitas.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。